Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of <0.3 g/d and the use of combination therapy targeting immune modulation and CKD management. In addition, they highlight the use of Nefecon, a disease-modifying therapy now recommended as a first-line treatment where approved.